Company: Kite Pharma
Job title: VP, Cellular Engineering
Christopher Bond Ph.D. is the research site head for the Santa Monica site. He received his Ph.D. Biochemistry from the University of Washington in 2000. Chris has worked biotech in pharma for over 18 years including Genentech, Oncomed, Juno Therapeutics, Celgene, Kite and Gilead. Chris has extensive experience in the discovery and development of adoptive cell therapies, monoclonal antibodies, as well as CRISPR gene editing. Prior to his work in adoptive cell therapy Chris led monoclonal and bi-specific antibody discovery and engineering programs targeting cancer stem cell antigens at Oncomed Pharmaceuticals.
The Progress of the Industry Leaders: Get your questions on the pipelines of the leading allogeneic developers answered 8:55 am
day: Day One